Norman D. Schwartz
Chairman, President, and CEO at Bio-Rad Laboratories Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Bio-Rad Laboratories Inc., 3 years.
Bio-Rad Laboratories Inc.
Director · Chairman & CEO
Chief executive roles
Bio-Rad Laboratories Inc.
· Chairman, President, and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2024 | Bio-Rad Laboratories Inc. | Option exercise | +2,320 | — | — |
| Sep 3, 2024 | Bio-Rad Laboratories Inc. | Shares withheld for tax | −1,241 | $334.31 | $414,879 |
| Sep 2, 2024 | Bio-Rad Laboratories Inc. | Option exercise | +1,805 | — | — |
| Sep 2, 2024 | Bio-Rad Laboratories Inc. | Shares withheld for tax | −965 | $337.32 | $325,514 |
| Sep 1, 2024 | Bio-Rad Laboratories Inc. | Option exercise | +3,005 | — | — |
| Sep 1, 2024 | Bio-Rad Laboratories Inc. | Shares withheld for tax | −1,607 | $337.32 | $542,073 |
| Sep 1, 2024 | Bio-Rad Laboratories Inc. | Option exercise | +2,081 | — | — |
| Sep 1, 2024 | Bio-Rad Laboratories Inc. | Shares withheld for tax | −801 | $337.32 | $270,193 |
| Sep 1, 2024 | Bio-Rad Laboratories Inc. | Option exercise | +1,266 | — | — |
| Sep 1, 2024 | Bio-Rad Laboratories Inc. | Shares withheld for tax | −545 | $337.32 | $183,839 |
| Aug 26, 2024 | Bio-Rad Laboratories Inc. | Gift | +57 | — | — |
| Aug 26, 2024 | Bio-Rad Laboratories Inc. | Gift | +57 | — | — |
| Dec 5, 2023 | Bio-Rad Laboratories Inc. | Gift | +49 | — | — |
| Dec 5, 2023 | Bio-Rad Laboratories Inc. | Gift | +49 | — | — |
| Nov 1, 2023 | Bio-Rad Laboratories Inc. | Option exercise | +35,000 | $119.80 | $4,193,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.